The propionic acidemia therapeutic market is estimated to be valued at USD 600.6 Mn in 2024 and is expected to reach USD 1,016.6 Mn by 2031, growing at a compound annual growth rate (CAGR) of 7.8% from 2024 to 2031.
Propionic acidemia (PA) is an autosomal recessive organic acid disorder caused due to deficiency of the mitochondrial enzyme propionyl-CoA carboxylase (PCC). PA results in accumulation of toxic metabolites namely propionic acid and methylcitrate in blood and other tissues. If left untreated, PA can cause life-threatening metabolic crisis, developmental delays, heart and liver problems. Currently, there is no cure for PA and treatment focuses on managing symptoms, preventing metabolic crisis and improving long-term outcomes.
Dietary therapy is the mainstay treatment and involves avoiding foods high in protein and limiting natural propionate precursors. Other treatment options include supplementation with carnitine, bicarbonate, glycine, antibiotic drugs metronidazole and protein restriction. Gene therapy and enzyme replacement therapy are upcoming alternative treatment modalities being researched for Propionic Acidemia Therapeutic Market.
Key Takeaways
Key players operating in the propionic acidemia therapeutic market are Horizon Therapeutics plc, Recordati Rare Diseases Inc., Dr. Schar AG/SPA, and MilUp Pharma GmbH.
Growing diagnosis of rare diseases like PA aided by newborn screeningprograms is fueling demand for targeted therapeutics. Early initiation of management ensures improved outcomes.
Advancements in gene therapy and development of novel drugs that curb accumulation of toxic metabolites or replace deficient enzyme are expected to transform PA treatment landscape in coming years.
Market Trends
Growing orphan drug development driven by government incentives is translating to larger product pipeline for conditions like PA. Several experimental drugs are under clinical evaluation.
Adoption of personalized medicine approach using biochemical monitoring and tailored dietary plans is gaining traction. This improves adherence and clinical response over long-term.
Market Opportunities
Development of first disease modifying drug that can reduce metabolic crisis and prevent complications presents multi-billion dollar commercial opportunity.
Availability of newborn screening for PA in developing nations can facilitate early diagnosis presenting opportunity to introduce management programs to improve quality of life.
Impact of COVID-19 on Propionic Acidemia Therapeutic Market Growth
The outbreak of COVID-19 pandemic has impacted the growth of Propionic Acidemia Therapeutic market globally. During the initial phase of pandemic, there was decline in demand for Propionic Acidemia Therapeutics as majority of healthcare resources and facilities were diverted towards treatment of COVID-19 patients. Lockdowns imposed by various governments further disrupted the supply chain networks delaying supplies of key raw materials for manufacturing of Propionic Acidemia Therapeutics.
However, with gradual lifting of lockdowns and focus on resuming healthcare services, the demand for Propionic Acidemia Therapeutics is recovering from Q3 2020 onwards. The manufacturers are focusing on ensuring uninterrupted supplies and meeting the growing needs. Several developmental activities related to new therapies were also paused temporarily but are now being continued adhering to requisite safety guidelines. Telehealth and telemedicine are assisting physicians in monitoring patients remotely and ensuring treatment continuity.
Going forward, focus on development of novel drug delivery mechanisms, personalized treatment plans and gene therapies are expected to drive the market growth post pandemic era. Collaboration between industry, academic research organizations and startups will be important for bringing innovative treatment solutions and accelerating the clinical research in this domain.
Propionic Acidemia Therapeutic Market by Geographical Regions
North America region currently accounts for the largest share of global Propionic Acidemia Therapeutic market in terms of value. This is majorly attributed to growing diagnosis rate supported by advanced healthcare infrastructure and increasing research funding in the region. Europe holds the second largest market followed by Asia Pacific region which is witnessing fastest growth and emerging as lucrative market especially in countries like China and India due to rising healthcare investment and growing medical tourism. The Middle East Africa region is expected to offer promising growth opportunities propelled by improving access to diagnosis and care.
Asia Pacific Region - Fastest growing market for Propionic Acidemia Therapeutics
The Asia Pacific region, especially countries like China and India, offer most promising growth opportunities for Propionic Acidemia Therapeutic market. This is ascribed to factors like rising healthcare expenditure, huge patient population, increasing medical insurance penetration, growing medical tourism and emergence of several local players in therapeutics manufacturing.
Rising public-private collaborations for improving diagnosis and initiating population-based screening programs are further augmenting the market growth. Moreover, growing RD investments by both international as well as domestic pharmaceutical players in this region would accelerate the clinical trial timelines and new product approvals, aiding the regional market growth. Favorable government policies and initiatives to strengthen healthcare infrastructure will continue to boost the adoption of advanced Propionic Acidemia Therapeutics.
Get more insights on : Propionic Acidemia Therapeutic Market
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
